The label-free detection market features intense competition among established healthcare technology companies, innovative biotechnology firms, and specialized detection system providers.

(Reuters) -Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a condition called peripheral artery disease. The company said ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a condition called peripheral artery disease.

New "Power of Private Brands" report from FMI shows continued strength and growth opportunities for retail own brands ...

BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.